You may not be able to teach old dogs new tricks, but drug companies can certainly try to get old drugs approved for new indications.
Gammagard Liquid is essentially antibodies purified from human plasma. It has been used to treat immunodeficiency conditions for almost 30 years.
Baxter hopes that the antibodies in Gammagard Liquid will attack and clear out beta-amyloid plaque in the brain, which many researchers believe is the cause of Alzheimer's disease. Elan
Unfortunately, human plasma is in short supply. Even if other makers of intravenous immunoglobulin (IVIG), such as Omrix Biopharmaceuticals
The best hope for patients is that Gammagard is found to be effective at reversing the disease, and that researchers are subsequently able to determine which antibodies in Gammagard are responsible for the positive effects. Those antibodies could then be formulated into a lab-made drug.
In the meantime, I'm not sure that Baxter will benefit that much from a positive clinical trial result. The increased demand might allow it to command a higher price tag for Gammagard for a while, but ultimately, a drug specifically for Alzheimer's disease will replace Gammagard. The antibodies that replace Gammagard could be purified from almost any IVIG product, so a FDA approval doesn't give Baxter researchers much of an advantage. Baxter seems to realize that its potential benefit is rather small, since it's convinced the National Institutes of Health to pick up part of the tab for the phase 3 trial.
More from The Motley Fool
Baxter International Inc.'s Cost-Cutting Efforts Pay Off in the Third Quarter
The medical supply company notches solid revenue and earnings gains but warns that fourth-quarter sales could be hurt by the impact of Hurricane Maria.
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Operational efficiencies continue to drive profits at the medical supply company.
Can These 3 High-Flying Healthcare Stocks Reach the Clouds?
Shares of Baxter International Inc., Intuitive Surgical, Inc., and Zoetis Inc. reached all-time highs recently, but can they keep it up?